Patient-driven assessment of disease activity in behçet's syndrome: Cross-cultural adaptation, reliability and validity of the turkish version of the behçet's syndrome activity score

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.77, 2013, Pages

  Yilmaz, Sedat ^a   Simsek, Ismail ^a   Cinar, Muhammet ^a   Erdem, Hakan ^a   Kose, Osman ^a   Yazici, Yusuf ^b   Pay, Salih ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Beh et's syndrome; Disease activity; Patient driven assessment

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ADAPTATION; ADULT; AGED; ARTICLE; BEHCET DISEASE; BEHCET DISEASE CURRENT ACTIVITY FORM; BEHCET SYNDROME ACTIVITY SCORE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURAL ANTHROPOLOGY; DISEASE ACTIVITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; QUESTIONNAIRE; ROUTINE ASSESSMENT OF PATIENT INDEX DATA; SCORING SYSTEM; TEST RETEST RELIABILITY; TURKEY (REPUBLIC); VALIDATION STUDY;

ADULT; BEHCET SYNDROME; CULTURAL CHARACTERISTICS; FEMALE; HUMANS; LANGUAGE; MALE; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TERTIARY CARE CENTERS; TURKEY;

EID: 84884938018     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. MUFTUOGLU A, YAZICI H, YURDAKUL S et al.: Behçet's disease. Relation of serum Creactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol 1986; 25: 235-9.
2. BHAKTA B, BRENNAN P, JAMES T, CHAMBERLAIN M, NOBLE B, SILMAN A: Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology 1999; 38: 728-33.
3. LAWTON G, BHAKTA B, CHAMBERLAIN M, TENNANT A: The Behçet's disease activity index. Rheumatology 2004; 43: 73-8.
4. HAMURYUDAN V, FRESKO I, DIRESKENELI H et al.: Evaluation of the Turkish translation of a disease activity form for Behçet's syndrome. Rheumatology 1999; 38: 734-6.
5. BALTACI M: A review on disease activity scores in Behçet's disease. Arthritis Res Ther 2003; 5 (Suppl. 2): 7.
6. DAVATCHI F, AKBARIAN M, SHAHRAM F, TEBBI M, CHAMS C, CHAMS H: Iran Behçet's disease dynamic activity measure. Abstracts of the XIIth European congress of rheumatology. Hungarian Rheumatol 1991; 32: 134.
7. FORBESS C, SWEARINGEN C, YAZICI Y: Behçet's Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with the Behçet's Disease Current Activity Form (BDCAF). Arthritis Rheum 2008; 58 (Suppl. 9); S854.
8. PINCUS T, ASKANASE AD, SWEARINGEN CJ: Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID3) scores are informative in patients with all rheumatic diseases. Rheum Dis Clin N Am 2009; 35: 819-27.
9. PINCUS T, YAZICI Y, CASTREJÓN I: Pragmatic and Scientific Advantages of MDHAQ/ RAPID3 Completion by All Patients at All Visits in Routine Clinical Care. Bull NYU Hosp Jt Dis 2012; 70: 30-6.
10. BEATON DE, BOMBARDIER C, GUILLEMIN F, FERRAZ MB: Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 2000; 25: 3186-9.
11. HAMURYUDAN V, FRESKO I, DIRESKENELI H et al.: Evaluation of the Turkish translation of a disease activity form for Behçet's syndrome. Rheumatology (Oxford) 1999; 38: 734-6.
12. CELIK S, FRESKO I, SUT N, BATUMLU NM, YAZICI H, YAZICI Y: Differences in pain and fatigue perception among a group of rheumatoid arthritis patients in the United States and in Turkey who have similar disease activity and functional status. Clin Exp Rheumatol 2010; 28: 884-7.
13. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
14. PINCUS T, CASTREJON I, BERGMAN MJ, YAZICI Y: Treat-to-target: not as simple as it appears. Clin Exp Rheumatol 2012; 30 (Suppl. 73): 10-20.
15. SMOLEN JS: Treat-to-target: rationale and strategies. Clin Exp Rheumatol 2012; 30 (Suppl. 73): 2-6.
16. YAZICI Y: Treat-to-target: measures. Clin Exp Rheumatol 2012; 30 (Suppl. 73): 7-9.
17. LUQMANI R: Treat-to-target in vasculitis: is this a sensible approach? Clin Exp Rheumatol 2012; 30 (Suppl. 73): 149-53.
18. TURKSTRA, Van VUGT RM, DIJKMANS BAC, YAZICI Y, YAZICI H: Results of a questionnaire on the treatment of patients with Behçet's syndrome: a trend for more intensive treatment. Clin Exp Rheumatol 2012; 30 (Suppl. 72): 10-13.
19. CASTREJÓN I, PINCUS T: Patient self-report outcomes to guide a treat-to-target strategy in clinical trials and usual clinical care of rheumatoid arthritis. Clin Exp Rheumatol 2012; 30 (Suppl. 73): 50-5.
20. PINCUS T, YAZICI Y, BERGMAN MJ: RAPID3: an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts - similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am 2009; 35: 773-8.
21. PINCUS T, BERGMAN MJ, YAZICI Y: RAPID3- An index of physical function, pain, and global status as "vital signs" to improve care for people with chronic rheumatic diseases. Bull NYU Hosp Jt Dis 2009; 67: 211- 25.